ClinicalTrials.Veeva

Menu

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

X

Xiamen Amoytop Biotech

Status and phase

Completed
Phase 1

Conditions

Chemotherapy Patients

Treatments

Drug: YPEG-Filgrastim

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01238562
TB1004CSF

Details and patient eligibility

About

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics of a single-dose of YPEG-Filgrastim in cancer patients receiving chemotherapy, and will establish dose-response relationships between YPEG-Filgrastim and Filgrastim(rhG-CSF, TOPNEUTER).

Enrollment

30 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: 18~70yrs
  • Signed informed consent
  • Confirmed malignant tumor patients by histopathological or cytological diagnosis, suitable for chemotherapy with carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin
  • Karnofsky score ≥70
  • Life expectancy >3 months
  • WBC≥3,500 per cubic milliliter, ANC≥1,500 per cubic milliliter, PLT≥100,000 per cubic milliliter
  • Normal coagulation function, no evidences of hemorrhage
  • Normal liver, heart, kidney function

Exclusion criteria

  • Pregnant or lactating females
  • Proven active infectious diseases (e.g. viral hepatitis, TB)
  • Not adequately controlled infections
  • Known hypersensitivity to filgrastim or any other components of the study drug
  • Unstable or uncontrolled cardiac disease or hypertension
  • Currently participated in any other clinical trials
  • Patients with previous or expected to receive systemic radiotherapy
  • Evidence of metastatic disease in bone marrow, brain, et al
  • Alcoholic or drug abusers
  • Other conditions which in the opinion of the investigator preclude enrollment into the study

Trial design

30 participants in 5 patient groups

YPEG-Filgrastim, 10mcg/kg
Experimental group
Treatment:
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
YPEG-Filgrastim, 20mcg/kg
Experimental group
Treatment:
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
YPEG-Filgrastim, 30mcg/kg
Experimental group
Treatment:
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
YPEG-Filgrastim, 45mcg/kg
Experimental group
Treatment:
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
YPEG-Filgrastim, 60mcg/kg
Experimental group
Treatment:
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim
Drug: YPEG-Filgrastim

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems